Z-005
Zonisamide solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H8N2O3S
化学文摘社编号:
分子量:
212.23
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
NS(CC1=NOC2=C1C=CC=C2)(=O)=O
InChI
1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
InChI key
UBQNRHZMVUUOMG-UHFFFAOYSA-N
基因信息
一般描述
Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
Yuto Ueda et al.
Biochemical and biophysical research communications, 428(3), 401-404 (2012-10-30)
The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats
D Marazziti et al.
European review for medical and pharmacological sciences, 16(15), 2102-2107 (2013-01-03)
Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles
S Dupont et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 29-35 (2012-11-01)
Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe
Andrea Romigi et al.
Epilepsy & behavior : E&B, 26(2), 170-174 (2013-01-15)
The purpose of this study was to evaluate the effects of zonisamide (ZNS) as adjunctive therapy on sleep-wake cycle and daytime somnolence in adult patients affected by focal epilepsy. Thirteen patients affected by focal epilepsy were recruited to undergo a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持